Alaunos Therapeutics, Inc. Common Stock

Day range

$2.01 – $2.36

Open

$2.32

Prev close

$2.28

Volume

405.37K

Market cap

$5.79M

Shares out

3.31M

P/E

—

P/S

1930.76

P/B

8.88

P/FCF

—

ROE

-654.1%

ROA

-281.3%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Listing compliance regainedOct 23, 2026

  On October 22, 2026, the Company received a letter from Nasdaq's Office of General Counsel advising that the Staff has confirmed that the Company has regained compliance with the Stockholders' Equity Requirement. As a result, Nasdaq has determined that this matter is now closed, the hearing before the Panel scheduled for November 10, 2026 has been cancelled, and the Company's common stock will continue to be listed and traded on The Nasdaq Capital Market.

• Delisting determinationOct 21, 2026

  On October 5, 2026, [the Company] received a written notice from the Staff informing the Company that its securities were subject to delisting from Nasdaq due to its continued non-compliance with the Stockholders' Equity Requirement unless the Company timely requested a hearing before the Nasdaq Hearings Panel.

• Equity compensation grantOct 13, 2026

  On October 12, 2026, the compensation committee of the Board approved the grant to Mr. Weis and Mr. Groenewald of options to purchase 50,000 and 10,000 shares of Common Stock, respectively, at an exercise price of $1.4357 per share.

• Underwriting agreementSep 22, 2026

  In connection with the Offering, the Company entered into a Placement Agency Agreement with Dawson James Securities, Inc. as the exclusive placement agent in connection with the Offering. As compensation to the Placement Agent, the Company paid ... a cash fee of 8% of the aggregate gross proceeds raised in the Offering and reimbursed certain expenses.

• Bylaw amendmentSep 17, 2026

  On September 16, 2026, the Board of Directors of Alaunos Therapeutics, Inc. approved and adopted the Second Amended and Restated By-Laws of the Company, effective immediately. The principal substantive change ... provide[s] that the presence in person or by proxy of the holders of one-third (1/3) in voting power of all outstanding shares of stock entitled to vote at a meeting of stockholders constitutes a quorum, rather than a majority.

Days to cover

1.0

Short interest

9.74K

Avg volume

4.31M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
  Benzinga· Feb 1, 2024
• Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
  Benzinga· Jan 10, 2024
• Why Dermata Therapeutics Shares Are Trading Higher By Over 57%; Here Are 20 Stocks Moving Premarket
  Benzinga· Jan 5, 2024
• Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
  Benzinga· Dec 19, 2023
• Why Motus GI Holdings Shares Are Trading Lower By Around 46%; Here Are 20 Stocks Moving Premarket
  Benzinga· Dec 19, 2023